Received Mar 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
One on January 17th, 2019, and the other on February 20th, 2019; One on January 17th, 2019, and the other on February 20th, 2019; This non-serious case was reported by a consumer via patient support programs and described the occurrence of drug dose administration interval too short in a 82-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 17-MAY-2019, the patient received the 3rd dose of Shingrix. On 20-FEB-2019, the patient received the 2nd dose of Shingrix. On 20-FEB-2019, not applicable after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: One on January 17th, 2019, and the other on February 20th, 2019). On 17-MAY-2019, the patient experienced extra dose administered (Verbatim: One on January 17th, 2019, and the other on February 20th, 2019). The outcome of the drug dose administration interval too short and extra dose administered were not applicable. Additional Information: GSK Receipt Date: 26-FEB-2026 The reporter was provided a summary of his vaccine records and states he was provided the zoster vaccine (Shingrix) at a pharmacy, he reports he received 2 doses at the pharmacy and summary states he received another dose at his doctor's office. The batch number was not provided and a request for this information has been made.
SHINGRIX